Induction of continuous complete remission with dual transcriptional modulation only, supports current experimental data, showing that PPARγ plays neither a tumor-suppressive nor an oncogenic role in advanced renal clear cell carcinoma, and that single-agent PPARγ agonists are unlikely to be effective for the treatment of this disease (Sanchez et al., 2018). Here, PPARG is linked to neoplasm.